KCM
TVRD

Kingdon Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Kingdon Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,167
Closed -$1.37M – 91
2022
Q2 		$1.37M Buy
+4,167
New +$1.46M 0.23% 61
2020
Q2 		– Sell
-4,019
Closed -$1.91M – 69
2020
Q1 		$1.91M Buy
+4,019
New +$2.18M 0.35% 45
2017
Q3 		– Sell
-458
Closed -$254K – 141
2017
Q2 		$254K Buy
+458
New +$291K 0.02% 98

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kingdon Capital Management's TVRD Position: Q2 2023 in Review

Kingdon Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 34,250 shares — an estimated $6.05M sold.

Kingdon Capital Management first reported a position in TVRD in Q2 2019 and held it in 16 quarters. The position peaked at $15.8M in Q1 2021. 137 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • Kingdon Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Kingdon Capital Management sold 34,250 Tvardi Therapeutics shares in Q2 2023, an estimated $6.05M.
  • Kingdon Capital Management first reported a position in Tvardi Therapeutics in Q2 2019 and held it in 16 quarters.
  • Kingdon Capital Management's Tvardi Therapeutics position peaked at $15.8M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Kingdon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.